Developing a risk assessment methodology for data protection

It appears that all parties involved in the current negotiations of the proposed data protection regulation are happy with the risk-based approach adopted in the proposal. If the Council’s amendments make it in the final draft of the regulation, then data controllers under certain circumstances will have one more thing to worry about. They will be obligated to proactively carry out a data protection impact assessment (DPIA) before processing certain types of data that may present high risk to the data subjects. This precautionary approach is meant to strengthen the accountability requirements in the regulation, and to instill a risk management culture among data controllers. Weiterlesen

Legal StartUps

Am 13.11.2014 veranstaltete das Institut für Rechtsinformatik eine Veranstaltung mit dem Titel „Legal StartUps“. Über 30 Personen bestehend aus Vertretern erfolgreicher StartUps, EULISP Studenten, Schwerpunkt Studenten, Mitarbeitern des IRI, Prof. Forgó sowie Prof. Heinze nahmen teil. Die Studenten des EULISP Programms stellten ihre Ideen für StartUps vor – die bereits erfolgreichen StartUps berichteten von ihrem Werdegang.


LEAB meeting took place in hanover

The first legal and ethics advisory board (LEAB) meeting for the AETIONOMY project took place in hanover on 10th October 2014. The distinguished board members included Richard Ashcroft, Professor of Bioethics at Queen Mary, University of London, Cecilia Magnussen Sjoeberg, Professor of IT law at Stockholm University, and Brecht Claerhout, Director of the data security specialists, Custodix (Belgium). The meeting was also attended by the patient groups Alzheimer Europe and European Brain Council as well as the project joint-coordinator UCB.
The AETIONOMY project is funded by the Innovative Medicines Initiative (IMI), a joint undertaking between the European Union and the pharmaceutical industry association EFPIA. AETIONOMY aims at a new “mechanism-based taxonomy” disease classification system, based upon the knowledge about the biological pathways involved in the aetiology of Alzheimer’s and Parkinson’s Disease to guide the classification of disease classes and subclasses.